Bristol-Myers Squibb and Incyte are leading the clinical development of emerging checkpoint modulators - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Bristol-Myers Squibb and Incyte are leading the clinical development of emerging checkpoint modulators

24 Oct 2017

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development.

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development. When looking at the cumulative number of clinical trials with immune checkpoint modulators from 2010 to Q2 2017, two companies, Bristol-Myers Squibb and Incyte, stand out as the main developers of emerging immune checkpoint modulators.

In Q2 2017, Bristol-Myers Squibb’s emerging checkpoint modulators were being explored in 33 clinical trials in Phase I to III, based on the clinical assessment of eight different drugs. Each of these eight products are associated with different emerging immune checkpoint targets, including indoleamine 2, 3-dioxygenase 1 (IDO1) and lymphocyte-activation gene 3 (LAG3) targets.

Based on the same cut-off point, Incyte’s emerging checkpoint modulators were evaluated in 26 clinical trials. In this period, Incyte developed fewer drugs than Bristol-Myers Squibb, with only three drugs covering three different targets. GlobalData’s analysis reveals that this high trial number is associated with the extensive clinical development of Incyte’s IDO1 inhibitor, epacadostat, across tumor types.

Related reports

GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, GDHC009PFR.